Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update

AIMS: Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment. METHODS: In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin. RESULTS: The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively. CONCLUSION: The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC. CLINICAL TRIAL REGISTRATION: www.chictr.org.cn identifier is ChiCTR-OOC-17014182.